SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a volatile relief rally driven by a combination of a derivatives-led short squeeze and shifting market sentiment regarding U.S.-Iran ceasefire negotiations. The community remains heavily divided, with bulls pointing to institutional accumulation as a foundation for growth while bears dismiss the price action as a temporary trap ahead of potential geopolitical escalation.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently caught in a volatile tug-of-war between institutional accumulation and broader market anxiety surrounding geopolitical tensions and macroeconomic uncertainty. While some traders are focused on bearish technical patterns, many in the community remain bullish, pointing to long-term structural upgrades and the potential for a breakthrough if key resistance levels are reclaimed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense market volatility driven by escalating geopolitical tensions in the Middle East, specifically the blockage of the Strait of Hormuz and reports of strikes on critical energy infrastructure. Investors are closely monitoring a looming policy deadline and conflicting headlines regarding potential ceasefires, fueling a debate among the community between positioning for a structural oil supply crisis or betting on a rapid de-escalation.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending due to intensifying speculation regarding a potential buyout or major partnership, fueled by activist pressure from Shah Capital to unlock shareholder value. While the company's core technology remains a focal point of community discussion, investor frustration is high due to ongoing volatility and silence from leadership regarding the status of key assets like the CIC vaccine.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust (QQQ) is experiencing high volatility as markets react to conflicting headlines regarding a potential ceasefire between the U.S. and Iran, with traders debating whether the latest extension of the diplomatic deadline is a genuine breakthrough or a strategic stall. The community remains deeply divided, with many expressing skepticism over the veracity of news sources while others remain focused on the potential for massive, policy-driven market swings.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

Strategy Inc. (STRC) is trending as investors capitalize on its perpetual preferred series, which offers a double-digit yield and serves as a liquidity engine for aggressive Bitcoin accumulation. While the community is actively debating the sustainability of this 'digital credit' flywheel and its potential impact on Bitcoin price action, many are treating the instrument as a high-yield vehicle to park capital while the company scales its treasury holdings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing intense trading activity as investors weigh the semiconductor sector's high valuation against geopolitical tensions and concerns over a potential AI bubble. Community discussion is split between those aggressively scalping the volatility for quick gains and bears positioning for a major market correction, with many traders closely monitoring semiconductor earnings and macroeconomic data as potential catalysts for a breakdown.

Direxion Shares ETF Trust - Direxion Small Cap Bear 3X ETF

Direxion Daily Small Cap Bear 3X Shares

The community is actively trading TZA to hedge against small-cap volatility and shifting economic expectations, with many users debating the sustainability of recent rallies and potential market downturns. Discussions heavily emphasize using inverse ETFs like TZA as a strategic tool to capitalize on market dips, while others express caution regarding the long-term decay risks inherent in holding leveraged products.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense community focus as traders debate the company's buyout potential and long-term valuation against larger competitors like Lilly and Novo Nordisk. Investors are actively analyzing recent clinical trial progress and the significant short interest, while weighing the impact of macro-geopolitical pressures on the stock's near-term price volatility.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is experiencing high volatility as markets react to conflicting headlines regarding a potential 45-day ceasefire between the U.S. and Iran, a recurring theme that investors are increasingly skeptical of. The community remains deeply divided, with many traders questioning the integrity of these reports while others are positioning for a relief rally based on potential de-escalation.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six h...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below Fifty Day Moving Average - What's Next?

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below Fifty Day Moving Average - What's Next...

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 8.4% Higher - Time to Buy?

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 8.4% - Time to Buy...

FY2030 Earnings Forecast for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Corvus Pharmaceuticals in a research report issued to clients...

Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Corvus Pharmaceuticals (NASDAQ:CRVS) Given Outperform Rating at Oppenheimer

Oppenheimer reiterated an "outperform" rating and set a $33.00 price target (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday...

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 6.5% After Earnings Miss

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% After Earnings Miss...

Corvus Pharmaceuticals Q4 Earnings Call Highlights

Corvus Pharmaceuticals (NASDAQ:CRVS) outlined expanding clinical plans for its selective ITK inhibitor soquelitinib while reporting higher research and development spending for 2025, reflecting a...

Corvus Pharmaceuticals (NASDAQ:CRVS) Issues Earnings Results, Misses Expectations By $0.01 EPS

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings...

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

CRVS
Corvus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVS News

CRVSCorvus Pharmaceuticals Inc